Journal Article Review Epublish
PubMed: 36451642 DOI: 10.7759/cureus.30821
Prognostic Models for Renal Cell Carcinoma in the Era of Immune Checkpoint Therapy.
Cureus 14(10):e30821
Authors: Andreea Parosanu, Ioana Miruna Stanciu, Cristina Pirlog, Cristina Orlov Slavu, Horia Cotan, Cristian Iaciu, Ana Maria Popa, Mihaela Olaru, Oana Moldoveanu, Baston Catalin, Cornelia Nitipir
Affiliations
- Oncology, Elias Emergency University Hospital, Bucharest, ROU.
- Medical Oncology, Elias Emergency University Hospital, Bucharest, ROU.
- Urology, Fundeni Clinical Institute, Bucharest, ROU.
Abstract
With recent advances in oncology, immune checkpoint inhibitors (ICIs) have become a milestone in immuno-oncology. Unfortunately, although ICIs have demonstrated improved clinical efficacy in a broad spectrum of cancers, many patients do not respond to this newer therapy. As a result, it is crucial to identify predictive factors of response to immunotherapy in patients with kidney cancer. This review discusses the research investigating potential biomarkers of response to ICIs in renal cell carcinoma.
MeSH
Cells, Neoplasms, Carcinoma, Renal Cell, Therapeutics